Literature DB >> 1688488

Postoperative recurrence of hepatocellular carcinoma.

T Nagao1, S Inoue, F Yoshimi, M Sodeyama, Y Omori, T Mizuta, N Kawano, Y Morioka.   

Abstract

Sixty-nine patients with hepatocellular carcinoma underwent curative hepatic resections as primary cases from 1981 to 1986. Seven patients died in the hospital after operation. The other 62 patients left the hospital and were closely followed for 25 to 78 months. Recurrence of carcinoma became obvious in 41 (66%) of 62 patients. The clinical and pathologic features of these 41 patients were not significantly different from those of the other patients. Recurrent tumors were found in the residual liver in 38 patients (93%), in the bone in 2 (5%), and in the lung in 1 (2%). Recurrence was diagnosed within 1 year, between 1 and 2 years, and more than 2 years after the operation in 22 (56%), 10 (26%), and 7 (18%) patients, respectively. It was difficult to determine the exact time of recurrence in two patients. There was a significant negative correlation between the size of primary tumor and time until recurrence; the larger the primary tumor, the shorter the time until recurrence. Among the 29 patients who underwent local excisions for their primary tumors, 19 recurrences were observed. Eighteen were found in the residual liver, in the same segment as the primary tumor, or in one near it. Larger hepatic resection for primary tumors is thus advocated to prevent recurrence.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1688488      PMCID: PMC1357889          DOI: 10.1097/00000658-199001000-00005

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  10 in total

1.  A GENERALIZED WILCOXON TEST FOR COMPARING ARBITRARILY SINGLY-CENSORED SAMPLES.

Authors:  E A GEHAN
Journal:  Biometrika       Date:  1965-06       Impact factor: 2.445

2.  Role of surgery in the treatment of primary carcinoma of the liver: a 31-year experience.

Authors:  T Y Lin; C S Lee; K M Chen; C C Chen
Journal:  Br J Surg       Date:  1987-09       Impact factor: 6.939

3.  One hundred hepatic resections. Indications and operative results.

Authors:  T Nagao; S Inoue; T Mizuta; H Saito; N Kawano; Y Morioka
Journal:  Ann Surg       Date:  1985-07       Impact factor: 12.969

4.  Hepatic resection for primary liver cancer. Report of 400 cases.

Authors:  M C Wu; X H Zhang; H Chen; X P Yao; G N Xu; B W Wu; J M Yang
Journal:  Chin Med J (Engl)       Date:  1986-03       Impact factor: 2.628

5.  Regression of aflatoxin B1-induced hepatocellular carcinomas by reduced glutathione.

Authors:  A M Novi
Journal:  Science       Date:  1981-05-01       Impact factor: 47.728

6.  Hepatic resection for hepatocellular carcinoma. Clinical features and long-term prognosis.

Authors:  T Nagao; S Inoue; S Goto; T Mizuta; Y Omori; N Kawano; Y Morioka
Journal:  Ann Surg       Date:  1987-01       Impact factor: 12.969

7.  Surgical treatment of 109 patients with symptomatic and asymptomatic hepatocellular carcinoma.

Authors:  C S Lee; J L Sung; L Y Hwang; J C Sheu; D S Chen; T Y Lin; R P Beasley
Journal:  Surgery       Date:  1986-04       Impact factor: 3.982

8.  Liver transplantation for malignant disease. Results in 93 consecutive patients.

Authors:  J G O'Grady; R J Polson; K Rolles; R Y Calne; R Williams
Journal:  Ann Surg       Date:  1988-04       Impact factor: 12.969

9.  Role of liver transplantation in cancer therapy.

Authors:  S Iwatsuki; R D Gordon; B W Shaw; T E Starzl
Journal:  Ann Surg       Date:  1985-10       Impact factor: 12.969

10.  Regeneration of human liver after hepatic lobectomy studied by repeated liver scanning and repeated needle biopsy.

Authors:  T Y Lin; C S Lee; C C Chen; K Y Liau; W S Lin
Journal:  Ann Surg       Date:  1979-07       Impact factor: 12.969

  10 in total
  42 in total

1.  Hepatocellular carcinoma.

Authors:  T Ezaki
Journal:  BMJ       Date:  1992-01-25

2.  Micrometastases of solitary hepatocellular carcinoma and appropriate resection margin.

Authors:  Ming Shi; Chang-Qing Zhang; Ya-Qi Zhang; Xiao-Man Liang; Jin-Qing Li
Journal:  World J Surg       Date:  2004-03-17       Impact factor: 3.352

3.  Non-surgical treatment of hepatocellular carcinoma.

Authors:  Philip J Johnson
Journal:  HPB (Oxford)       Date:  2005       Impact factor: 3.647

4.  Orthotopic liver transplantation as a rescue operation for recurrent hepatocellular carcinoma after partial hepatectomy.

Authors:  Zhuo Shao; Rocio Lopez; Bo Shen; Guang-Shun Yang
Journal:  World J Gastroenterol       Date:  2008-07-21       Impact factor: 5.742

5.  Characterization of six tumor suppressor genes and microsatellite instability in hepatocellular carcinoma in southern African blacks.

Authors:  C Martins; M A Kedda; M C Kew
Journal:  World J Gastroenterol       Date:  1999-12       Impact factor: 5.742

6.  Recurrence after resection of alpha-fetoprotein-positive hepatocellular carcinoma.

Authors:  X D Zhou; Z Y Tang; Y Q Yu; B H Yang; J Z Lu; Z Y Lin; Z C Ma; B H Zhang
Journal:  J Cancer Res Clin Oncol       Date:  1994       Impact factor: 4.553

Review 7.  Hepatocellular carcinoma: is current therapy really altering outcome?

Authors:  P J Johnson
Journal:  Gut       Date:  2002-10       Impact factor: 23.059

8.  Intrahepatic distant metastasis and metachronous multicentric occurrence in solitary hepatocellular carcinoma of less than five centimeters in diameter.

Authors:  M Yamamoto; M Matsuda; Y Iimuro; H Fujii; K Nagahori; T Ainota
Journal:  Surg Today       Date:  1993       Impact factor: 2.549

9.  Early recurring hepatocellular carcinoma after partial hepatic resection: preoperative CT findings.

Authors:  J H Lim; H J Jang; E Y Kim; C K Park; J W Joh; Y I Kim
Journal:  Korean J Radiol       Date:  2000 Jan-Mar       Impact factor: 3.500

10.  Keratin 19 marks poor differentiation and a more aggressive behaviour in canine and human hepatocellular tumours.

Authors:  Renee G H M van Sprundel; Ted S G A M van den Ingh; Valeer J Desmet; Azeam Katoonizadeh; Louis C Penning; Jan Rothuizen; Tania Roskams; Bart Spee
Journal:  Comp Hepatol       Date:  2010-02-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.